Catheter Precision Announces First Procedures in France as LockeT Expansion Continues
Catheter Precision (NYSE:VTAK), a US-based medical device company, has announced the successful completion of its first LockeT procedures in France at CHU Rennes. The procedures were led by Professor Raphael Martins and his team, marking a significant milestone in the company's European expansion.
This development follows the recent CE Mark approval for LockeT, a device designed to improve procedural efficiency and patient outcomes after cardiac ablation procedures. CHU Rennes, which is also a commercial partner for VTAK's VIVO product line, represents the company's growing presence in the European medical device market.
Catheter Precision (NYSE:VTAK), azienda statunitense del settore dei dispositivi medici, ha annunciato il successo delle sue prime procedure LockeT in Francia presso il CHU Rennes. Le procedure sono state guidate dal professore Raphael Martins e dal suo team, segnando un traguardo importante nell'espansione europea dell'azienda.
Questo sviluppo segue la recente approvazione del marchio CE per LockeT, un dispositivo progettato per migliorare l'efficienza delle procedure e gli esiti per i pazienti dopo gli interventi di ablazione cardiaca. Il CHU Rennes, che è anche partner commerciale per la linea di prodotti VIVO di VTAK, rappresenta la crescente presenza dell'azienda nel mercato europeo dei dispositivi medici.
Catheter Precision (NYSE:VTAK), una compañía estadounidense de dispositivos médicos, ha anunciado la finalización exitosa de sus primeras procedimientos LockeT en Francia en el CHU Rennes. Los procedimientos estuvieron a cargo del profesor Raphael Martins y su equipo, marcando un hito significativo en la expansión europea de la empresa.
Este avance se produce tras la reciente aprobación del marcado CE para LockeT, un dispositivo diseñado para mejorar la eficiencia de los procedimientos y los resultados de los pacientes tras las ablaciones cardíacas. El CHU Rennes, que también es socio comercial de la línea de productos VIVO de VTAK, representa la creciente presencia de la compañía en el mercado europeo de dispositivos médicos.
Catheter Precision (NYSE:VTAK), 미국 기반의 의료기기 회사가 CHU Rennes에서 프랑스 최초의 LockeT 시술을 성공적으로 마쳤다고 발표했습니다. 해당 시술은 라파엘 마르틴스 교수와 그의 팀이 주도했으며, 회사의 유럽 확장에 있어 중요한 이정표가 되었습니다.
이번 성과는 LockeT의 최근 CE 인증 획득에 따른 것으로, 이 장치는 심장 절제술 후 시술 효율성과 환자 결과 개선을 목표로 설계되었습니다. VTAK의 VIVO 제품군에 대한 상업 파트너이기도 한 CHU Rennes는 유럽 의료기기 시장에서 회사의 존재감이 커지고 있음을 보여줍니다.
Catheter Precision (NYSE:VTAK), une entreprise américaine de dispositifs médicaux, a annoncé la réussite de ses premières procédures LockeT en France au CHU Rennes. Les interventions ont été dirigées par le professeur Raphael Martins et son équipe, marquant une étape importante dans l'expansion européenne de la société.
Cette avancée fait suite à la récente obtention du marquage CE pour LockeT, un dispositif conçu pour améliorer l'efficacité des procédures et les résultats pour les patients après des ablations cardiaques. Le CHU Rennes, qui est également partenaire commercial de la gamme de produits VIVO de VTAK, illustre la présence croissante de la société sur le marché européen des dispositifs médicaux.
Catheter Precision (NYSE:VTAK), ein US-amerikanisches Medizintechnikunternehmen, hat die erfolgreiche Durchführung seiner ersten LockeT-Verfahren in Frankreich am CHU Rennes bekanntgegeben. Die Eingriffe wurden von Professor Raphael Martins und seinem Team geleitet und markieren einen wichtigen Meilenstein in der europäischen Expansion des Unternehmens.
Diese Entwicklung folgt auf die kürzliche CE-Zulassung für LockeT, ein Gerät, das entwickelt wurde, um die Effizienz von Eingriffen und die Ergebnisse für Patienten nach kardialen Ablationsverfahren zu verbessern. Das CHU Rennes, das zudem kommerzieller Partner für VTAKs VIVO-Produktlinie ist, steht für die wachsende Präsenz des Unternehmens auf dem europäischen Medizintechnikmarkt.
- First successful LockeT procedures completed in France, expanding European market presence
- Partnership with CHU Rennes extends across multiple product lines (LockeT and VIVO)
- Rapid market entry following CE Mark approval indicates strong market demand
- None.
FORT MILL, S.C., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company and leader in innovative cardiac electrophysiology solutions, is proud to announce the first LockeT procedures in France. This milestone demonstrates significant progress in the adoption and commercialization of its technologies across the continent.
The first procedures with LockeT in France and Europe were successfully completed at CHU Rennes, led by Professor Raphael Martins and his esteemed team. It was recently announced that CHU Rennes is also a commercial partner for the Company’s VIVO product line.
Fatih Ayoglu, Sales Manager for EMEA & APAC at Catheter Precision, said, “This marks a pivotal moment in the clinical rollout of LockeT, which is designed to enhance procedural efficiency and patient outcomes after cardiac ablation procedures. Completing product evaluations so soon after the CE Mark was received is a testament to the need of a product like LockeT in the European Market. We look forward to expanding the commercial footprint and continuing our partnership with Professor Martins and the team at CHU Rennes.”
About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.
About VIVO™
Catheter Precision’s VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE Mark.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
Investor Relations
973-691-2000
IR@catheterprecision.com
# # #
FAQ
What is the significance of Catheter Precision's (VTAK) first LockeT procedures in France?
Where were the first LockeT procedures performed in France by Catheter Precision (VTAK)?
What is the purpose of Catheter Precision's (VTAK) LockeT device?
How has CHU Rennes partnered with Catheter Precision (VTAK)?
What does the rapid adoption of LockeT indicate for Catheter Precision (VTAK) in Europe?
